Conference Coverage

Medically suspect criterion can determine bariatric surgery coverage


 

FROM ASMBS 2021

Waiting for hypertension to become less treatable

The results Dr. Raftopoulos presented “are not surprising, because they confirm the hypothesis that earlier intervention in the course of a disease like hypertension is more likely to be successful,” commented Bruce D. Schirmer, MD, a professor of surgery at the University of Virginia, Charlottesville, and designated discussant for the report.

The policy followed by some health insurers to delay coverage for bariatric surgery until patients fail three medications “forces patients with more treatable hypertension to wait until their disease worsens and becomes less treatable before they can receive appropriate treatment,” he said.

Dr. Schirmer attributed the motivation for this approach to a “despicable” and “reprehensible” reason: “Actuarial calculations that show paying for curative therapy is not cost effective in the short term. The duration of a patient’s policy may not be long enough to yield a positive financial outcome, so it becomes more appropriate to deny optimal care and have patients become sicker from their disease.”

“I applaud the authors for accumulating the data that point out this unfortunate rule of some insurance companies,” Dr. Schirmer added.

The practice is comparable with an insurer requiring that a patient’s cancer must be metastatic before allowing coverage for treatment, commented Ann M. Rogers, MD, professor and director of the Penn State University surgical weight loss program in Hershey, Penn., and a moderator of the session.

Dr. Raftopoulos, Dr. Schirmer, and Dr. Rogers had no disclosures.

Pages

Recommended Reading

FDA approves ‘game changer’ semaglutide for weight loss
MDedge Endocrinology
New obesity target? Dopamine circuit in brainstem affects satiety
MDedge Endocrinology
Waist circumference a marker for NAFL in type 1 diabetes
MDedge Endocrinology
Obesity amplifies harmful effects of alcohol on the liver
MDedge Endocrinology
‘Twincretin’ meets primary endpoints in five pivotal diabetes trials
MDedge Endocrinology
FDA: More metformin extended-release tablets recalled
MDedge Endocrinology
Bariatric surgery tied to fewer HFpEF hospitalizations
MDedge Endocrinology
Healthy with obesity? The latest study casts doubt
MDedge Endocrinology
Bariatric surgery’s cardiovascular benefit extends to 7 years
MDedge Endocrinology
Bariatric surgery cuts insulin needs in type 1 diabetes with severe obesity
MDedge Endocrinology